Muutke küpsiste eelistusi

Advances in Genetics, Volume 108 [Kõva köide]

Edited by (Honorary Clinical Professor, William Harvey Research Institute, Queen Mary University of London, UK)
  • Formaat: Hardback, 396 pages, kõrgus x laius: 229x152 mm, kaal: 770 g
  • Sari: Advances in Genetics
  • Ilmumisaeg: 16-Nov-2021
  • Kirjastus: Academic Press Inc
  • ISBN-10: 0128237856
  • ISBN-13: 9780128237854
Teised raamatud teemal:
Advances in Genetics, Volume 108Suurem pilt
  • Formaat: Hardback, 396 pages, kõrgus x laius: 229x152 mm, kaal: 770 g
  • Sari: Advances in Genetics
  • Ilmumisaeg: 16-Nov-2021
  • Kirjastus: Academic Press Inc
  • ISBN-10: 0128237856
  • ISBN-13: 9780128237854
Teised raamatud teemal:
Püsilink: https://www.kriso.ee/db/9780128237854.html
Märksõnad:

Advances in Genetics, Volume 108 provides the latest information on genetics, presenting new medical breakthroughs that are occurring as a result of advances in our knowledge of the topic. The book continually publishes important reviews of the broadest interest to geneticists and their colleagues in affiliated disciplines, with this new release including chapters on Clinical applications of cancer genetics and genomics, Epigenetic mutations in childhood tumors- the paradigm of Wilms tumor, Preventive population genomics-the model of BRCA related cancers, Recent advances of PARP inhibitors in medical oncology, Role of single cell and liquid biopsy in cancer research and clinical applications.

Other chapters cover Recent advances and clinical utility of prostate cancer genomics, Recent advances in lung cancer genomics- applications in targeted therapy, and more.

  • Critically analyzes future directions for the study of clinical genetics
  • Written and edited by recognized leaders in the field
  • Presents new medical breakthroughs that are occurring as a result of advances in our knowledge of genetics
Contributors ix
Preface xi
1 Preventive population genomics: The model of BRCA related cancers
1(34)
Dan Reisel
Chawan Baran
Ranjit Manchanda
1 Preventive population genomics: The model of BRCA related cancers
2(4)
2 The traditional clinical genetic testing approach
6(2)
3 Population genomics: The Jewish BRCA model
8(5)
4 Population genomics: BRCA testing in the wider general population
13(2)
5 Pre-test genetic education and counseling: Yes or No?
15(3)
6 Population genomics: Beyond BRCA
18(3)
7 Conclusions
21(14)
Disclosures
22(1)
References
22(13)
2 PARP inhibitors in hereditary breast and ovarian cancer and other cancers: A review
35(46)
Prashant Mehta
Sneha J. Bothra
1 Introduction
36(1)
2 Molecular concepts with HBOC and PARPi
37(1)
3 DNA repair systems
38(6)
4 PARP inhibitors
44(5)
5 Toxicity
49(4)
6 Management of toxicities
53(1)
7 Indications of use of PARP inhibitors
54(7)
8 Mechanisms of resistance
61(1)
9 Overcoming resistance: PARPi and combination with other agents
61(10)
10 Functional cure in advanced disease?
71(1)
11 Future developments
72(9)
References
72(9)
3 Novel omics technology driving translational research in precision oncology
81(66)
Anubhav Basu
Anshul Budhraja
Juwayria
Dasari Abhilash
Ishaan Gupta
1 Introduction
82(2)
2 Challenges in cancer
84(6)
3 Novel genomic technologies and their application in precision oncology
90(41)
4 Conclusion: Integration, challenges and future directions
131(16)
References
134(13)
4 Genetics of prostate cancer and its utility in treatment and screening
147(54)
S. Benafif
H. Ni Raghallaigh
J. McHugh
R. Eeles
1 Introduction
148(4)
2 Germline mutations and prostate cancer
152(8)
3 Common variants contributing to prostate cancer risk
160(10)
4 Current management of men with increased risk of prostate cancer development
170(6)
5 Current guidance on germline and somatic testing in prostate cancer
176(3)
6 Personalized treatment for prostate cancer
179(8)
7 Conclusions and future directions
187(14)
References
190(11)
5 Recent advances in lung cancer genomics: Application in targeted therapy
201(76)
Neha Pathak
Sindhura Chitikela
Prabhat Singh Malik
1 Introduction
202(1)
2 Oncogene addiction
203(1)
3 One disease model to molecular classification
204(3)
4 Ethnic variations in genomic profile
207(1)
5 Intra-tumoral heterogeneity
208(1)
6 Clinical implications of genomic understanding of lung cancer
208(1)
7 Biomarker testing in lung cancer
209(1)
8 Methods of biomarker testing
210(12)
9 Therapeutic landscape of genomics directed treatments in NSCLC
222(25)
10 Immunotherapy and genomics
247(2)
11 Small cell lung cancer
249(1)
12 Conclusion
250(27)
References
252(25)
6 Nutrigenetics and nutrigenomics--A personalized approach to nutrition
277(64)
Maninder Kaur Ahluwalia
1 Introduction
278(1)
2 Obesity--A thrifty response
279(1)
3 Nutrigenetics: Genetic variants-targets of personalized approach
280(9)
4 Nutrigenomics: Diet modulates expression of the genome
289(7)
5 PPARy at the crossroads of nutrigenetics and nutrigenomics
296(2)
6 PCSK9 Proprotein Convertase Subtilisin/Kexin Type 9: A target for nutraceutical intervention
298(2)
7 Epigenetics: Genes are not destiny
300(7)
8 Diet-gut microbiota interactions
307(5)
9 Eating behaviors
312(4)
10 Resveratrol: A multifaceted nutraceutical
316(2)
11 Conclusion
318(23)
References
318(23)
7 Next-generation microbial drugs developed from microbiome's natural products
341
Keshab Bhattarai
Keshab Bhattarai
Bikash Baral
1 Introduction
342(1)
2 Microbiome, metagenome, and metabolites
343(1)
3 Host-microbes' interactions and metabolic trade-off
344(3)
4 Metabolite's bioactivity and associated diseases
347(3)
5 Microsomes metabolites as therapeutic leads
350(3)
6 Characterization of microsomes SMs
353(6)
7 Microbiome habitats
359(6)
8 Xenobiotics
365(4)
9 Challenges and future perspectives
369
References
370
Professor Kumar has considerable previous experience in writing and editing books and journals related to genetics and genomics. His books include Genomics and Clinical Medicine and Genomics and Health in the Developing World. He founded and leads the new open access journal Applied and Translational Genomics, published by Elsevier. He has published 40 articles in the journals literature. Professor Dhavendra Kumar is a Visiting Professor, Genomic Policy Unit, Faculty of Life Sciences and Education, The University of South Wales and Consultant in Clinical Genetics at the University Hospital of Wales, Institute of Medical Genetics, Cardiff University, Cardiff, United Kingdom. He is one of the Consultants for the All Wales Medical Genetics Service and the lead Clinician for Clinical Cardiovascular Genetics. After qualifying in Medicine from the King Georges Medical College, University of Lucknow, India, he completed postgraduate training in Pediatrics with an MD. Since 1980 he has pursued a career in Medical Genetics in the UK. In 1990 he became a Diplomate of the American Board of Medical Genetics. He is a Fellow of the American College of Medical Genetics (FACMG) and as well as Royal Colleges of Physicians (FRCP-London and FRCP-Ireland) and Pediatrics and Child Health (FRCPCH-UK).

In 2015, he was conferred with the higher degree of DSc by his Alma Mater, King Georges Medical University, Lucknow (UP, India) based on his life-time contributions and achievements to genetic and genomic applications in medicine and health.